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ABSTRACT
Indolicidin is a host defense tridecapeptide that
inhibits the catalytic activity of HIV-1 integrase
in vitro. Here we have elucidated its mechanism of
integrase inhibition. Using crosslinking and mass
spectrometric footprinting approaches, we found
that indolicidin interferes with formation of the
catalytic integrase-DNA complex by directly binding
DNA. Further characterization revealed that the
peptide forms covalent links with abasic sites.
Indolicidin crosslinks single- or double-stranded
DNAs and various positions of the viral cDNA with
comparable efficiency. Using truncated and chemi-
cally modified peptides, we show that abasic site
crosslinking is independent of the PWWP motif but
involves the indolicidin unique lysine residue and
the N- and C- terminal NH2 groups. Because indo-
licidin can also inhibit topoisomerase I, we believe
that multiple actions at the level of DNA might be
a common property of antimicrobial peptides.
INTRODUCTION
Several oligopeptides have been reported to inhibit HIV-1
integrase (IN) [for review, see (1)]. We recently discovered
that indolicidin (Figure 1), an antimicrobial cationic tride-
capeptide, inhibits IN in vitro and that multimerization of
this peptide greatly enhances its potency (2). Indolicidin has
been isolated from the cytoplasmic granules of bovine neutro-
phils (3) and belongs to the cathelicidin family of the host
defense peptides (HDPs) (4). HDPs play a key role in the
innate host defense system and are thought to constitute the
ﬁrst line of defense against invading microorganisms. They
represent an abundant and diverse group of molecules pro-
duced by a broad range of cells and tissues from invertebrate,
plant and animal species [for review see (5)]. Cathelicidin
HDPs have been found in many mammals including humans
but also in primitive vertebrates such as hagﬁshes (6). Cathe-
licidin HDPs are mainly found in the cytoplasmic granules
of circulating neutrophils. They are also expressed in non-
myeloid cells in skin and mucosal surfaces. Human cathe-
licidin peptide (LL-37) deﬁciency in neutrophils has been
correlated with Kostmann syndrome, a severe congenital neu-
tropenia with chronic periodontal disease (6).
Cathelicidin HDPs exert their antimicrobial action through
interactions with cell membranes and pore formation but
other killing mechanisms based on interactions with internal
microbial targets have also been reported. For instance, some
cathelicidin HDPs interfere with DNA/RNA/protein synthesis
[for review see (5,6)]. They can neutralize microbial endotox-
ins by direct binding, promote wound healing and modulate
the immune response. Therefore, cathelicidin HDPs have
been the focus of an increased interest as potential novel
therapeutic agents (7).
Cathelicidin peptides share common features with other
HDPs including a net positive charge and an overall amphi-
pathic topology. They can be categorized according to their
secondary structure and amino acid enrichment. They are
either a-helical, b-hairpin or linear with enrichment in pro-
line or tryptophan residues (6). Indolicidin is a linear natural
13mer cationic cathelicidin HDP containing ﬁve tryptophan
(Trp) and two proline (Pro) residues, two of which are within
Trp-Pro-Trp tandem repeats (PWWP motif). Indolicidin has a
broad spectrum of activity; it is antibacterial (3), antifungal
(8), antiparasitic (9,10), antiviral (11,12) and an inhibitor of
aminoglycoside antibiotic resistance enzymes (13). The solu-
tion structure of indolicidin reveals multiple conformations of
the peptide in aqueous solution and in membrane-mimicking
environments suggesting that structural plasticity accounts for
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doi:10.1093/nar/gkl667its multiple effects (14). Its mechanism of action has been
related to cell membrane permeabilization (15–17), but indoli-
cidin also inhibit DNA synthesis leading to Escherichia coli
ﬁlamentation (18). Thus it is plausible that indolicidin exerts
its antimicrobial activity by targeting nucleic acids.
In the present study, we demonstrate that indolicidin
and its arginine (Arg)-free analog RIN-25 (2) (Figure 1)
directly bind DNA and interfere with formation of the IN–
DNA complex interfere with the formation of IN-DNA com-
plexes. Both peptides also bind abasic site-containing DNA
(abDNA). The efﬁciencies of crosslinking are comparable
for double- and single-strand abDNA at different DNA posi-
tions. Using truncated and chemically modiﬁed peptides,
we dissected the primary structural features of the peptide
that are essential for efﬁcient crosslinking to abDNA. Our
results provide new insight into the mechanism of action of
the natural antimicrobial indolicidin.
MATERIALS AND METHODS
DNA oligonucleotides, HIV-1 integrase and peptides
Oligonucleotides were purchased from IDT Inc. (Coralville,
IA) and puriﬁed on a 20% (19:1) denaturing polyacrylamide
gel using UV shadow. Puriﬁed oligonucleotides were 50 end
labeled by T4-polynucleotide kinase (New England Biolabs,
Inc. Beverly, MA) as described previously (19). The wild-
type recombinant IN was expressed and puriﬁed as described
previously (20). The synthesis of indolicidin analogs has been
described in detail separately (2).
Schiff base assay
The Schiff base assay was performed as described previously
(19,21). Brieﬂy, uracil-containing oligonucleotides corre-
sponding to the 21 last bases of the HIV-1 U5 long terminal
repeats (LTR) were 50 end labeled and annealed to their com-
plementary strand. The resulting duplexes were then treated
by 1 U of uracil DNA glycosylase (UDG) (Gibco BRL/Life
Technologies) for 1 h at 37 C in order to generate an abasic
site.
Peptides were incubated with 500 nM IN for 15 min at
room temperature in a total volume of 9 ml with a buffer con-
taining 25 mM MOPS, pH 7.2, 5 mM NaCl, 7.5 mM MgCl2,
and 14.3 mM 2-mercaptoethanol. Then 1 mlo f5 0 end labeled
abDNA (20 nM ﬁnal) was added and the reaction was
incubated for an extra 30 min at room temperature.
When IN was not present in the reaction, peptides were
incubated with 20 nM of 50 end labeled abDNA in the
same volume and buffer for 15 min at room temperature.
IN-DNA crosslinks were reduced by 1 ml of 1 M sodium
borohydride (NaBH4, 0.1 M ﬁnal). After 5 min at room tem-
perature, samples were treated with one volume of 2· SDS–
tricine gel-loading buffer, heated 5 min at 95 C and loaded
onto 12–20% tricine–SDS polyacrylamide gels (Invitrogen
Corp., Carlsbad, CA). Gels were exposed overnight and
analyzed using a Molecular Dynamics Phosphorimager (GE
Healthcare, Waukesha, WI). Densitometric analyses were
performed using ImageQuant from the Molecular Dynamics
software package. Each lane was quantiﬁed for crosslinking
product formation, which was expressed as a fraction of the
total DNA per lane and plotted using Prism 4.0 (Graphpad
Software Inc., San Diego, CA).
Mass spectometry
Peptides in their free form and complexed with either DNA or
IN were subjected to modiﬁcation with N-hydroxysuccinimi-
dobiotin (NHS-Biotin) (Pierce, Rockford, IL). NHS-Biotin
reacts speciﬁcally with primary amines on peptides resulting
in covalent addition of a biotin molecule (226 Da). After
incubation at 37 C for 30 min, the reactions were quenched
with 10 mM lysine in its free amino acid form. The peptides
were puriﬁed by ZipTip according to the manufacturer’s
instructions (Millipore Corporation, Bedford, MA) and
subjected to mass spectrometric (MS) analysis. MS spectra
were recorded with a Shimadzu Axima-CFR MALDI-TOF
instrument (Shimadzu Scientiﬁc Instruments, Columbia,
MD) using a-cyano-4-hydroxycinnamic acid as matrix.
Topoisomerase I (Top1) assay
For the Top1-mediated DNA relaxation assay, reaction mix-
tures (10 ml ﬁnal volume) contained 0.3 mg supercoiled
fX174 DNA in reaction buffer [10 mM Tris–HCl, pH 7.5,
50 mM KCl, 5 mM MgCl2, 0.1 mM EDTA, and 15 mg/ml
bovine serum albumin (BSA)] and 2 U of Top1 (22). Reac-
tions were performed at 37 C for 30 min with Top1 in the
absence or presence of varying concentrations of indolicidin.
The reactions were terminated by the addition of 0.5% SDS
Figure 1. Structure and sequence of indolicidin and its derivative RIN-25. (A) Chemical structure of indolicidin. (B) Sequences of indolicidin and RIN-25.
Amino acids are indicated as single letter code.
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30 min at 50 C. Next, 1.2 mlo f1 0 · gel-loading buffer
(20% Ficol 400; 0.1 M Na2EDTA, pH 8.0, 1.0% SDS, and
0.25% bromphenol blue) was added and reactions mixtures
were loaded onto 1% agarose gels made in 1· TBE buffer.
Gels were run in 1· TBE. After electrophoresis, DNA bands
were stained in 10 mg/ml of ethidium bromide and visualized
by transillumination with ultraviolet light (300 nm).
In the fX174 DNA unwinding assay, reactions were per-
formed in a 10 ml ﬁnal volume at 37 C in reaction buffer
(see above) with 0.3 mg supercoiled fX174 DNA and 2 U
of Top1 per reaction. First, the reactions were performed
with Top1 alone for 30 min followed by incubation in the
presence or absence of varying concentrations of indolicidin
for another 30 min. The reactions were terminated by addi-
tion of 0.5% SDS and 0.5 mg/ml proteinase K and processed
as described in the relaxation assay. After electrophoresis,
DNA bands were stained in 10 mg/ml of ethidium bromide
and visualized by transillumination with ultraviolet light
(300 nm).
RESULTS
Indolicidin and RIN-25 inhibit HIV-1
integrase-DNA binding
To investigate the inﬂuence of indolicidin and its Arg-free
analog RIN-25 (Figure 1) (2) on IN-DNA binding, we used
the Schiff base crosslinking method (19,21) that can trap
IN chemically onto its DNA substrate (Figure 2A). In this
assay, an abasic site is ﬁrst generated in an uracil-containing
DNA molecule using uracil DNA glycosylase. The abasic site
then reacts with an e-amino group of a Lys residue present in
its vicinity to generate an imine. This imine is subsequently
stabilized by reduction with sodium borohydride (NaBH4)
into a covalent complex.
The data depicted in Figure 2 indicate that both indolicidin
and RIN-25 inhibit IN-DNA crosslinking. Titration of
increasing concentrations of the peptides in the reaction
mixture correlates with a decrease of the gel band intensity
corresponding to the IN–DNA complex and with a concomi-
tant increase of the band intensity corresponding to a peptide–
DNA complex (Figure 2B and C). Unlike indolicidin, RIN-25
fully suppressed IN-DNA crosslinking at the peptide concen-
tration range of 37–333 mM (Figure 2C). These IN-DNA
binding results correlate well with the inhibition proﬁles of
IN catalytic activity by these two peptides (2).
These results demonstrate that both indolicidin and its
analog RIN-25 inhibit IN catalytic activity by competing
with the enzyme for DNA binding.
Indolicidin crosslinks with a similar efficiency
single- and double-stranded abDNA at
different DNA positions
We next investigated the crosslinking of indolicidin and its
derivative RIN-25 to abDNA in the absence of IN. In addition
Figure 2. Inhibition of integrase-DNA binding by indolicidin and RIN-25. (A) Schematic representation of the Schiff base assay mechanism (19,21).
(B and C) Gel images of representative experiments performed with indolicidin and RIN-25.
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nucleotide containing an abasic site at the same nucleotide
position was tested. Figure 3 shows that both indolicidin
and RIN-25 crosslink efﬁciently single- and double-stranded
abDNA (Figure 3A, left panel and data not shown for
RIN-25). Crosslinking can only be observed after reduction
of the complex by NaBH4 treatment (Figure 3A, right panel
and Figure 2A). Crosslinking products appear at sub-
micromolar concentrations of peptide (Figure 3A) and as fast
asin30s(Figure3B).Therateofcrosslinkformationissimilar
for single- and double-stranded abDNA (Figure 3B).
We next wanted to investigate the inﬂuence of the abasic
site position on the efﬁciency of crosslinking by indolicidin.
A single abasic site was introduced in the duplex oligo-
nucleotide at positions ranging from  1t o 12 from
the IN cleavage site (Figure 3C). Indolicidin and RIN-25
(data not shown) crosslink each oligonucleotide with similar
efﬁciency suggesting that abDNA crosslinking by indolicidin
and RIN-25 is independent of the abasic site position on the
DNA sequence. We also found that indolicidin crosslinks
abDNA independently of the presence of divalent metal
(data not shown).
These results demonstrate that indolicidin and its deriva-
tive RIN-25 bind with similar efﬁciency to single- and
double-stranded abDNAs.
The N-terminus region of indolicidin is required for
DNA binding
We next wanted to determine the structural requirements of
indolicidin for DNA binding. We studied the efﬁciency
of several indolicidin derivatives for abDNA crosslinking
(Figure 4A). Replacing the two C-terminal protonated
Arg residues of indolicidin by two Pro residues in RIN-25
(Figure 4A) slightly reduced crosslink formation
(Figure 4B). However, when the Pro-Trp-Trp-Pro (PWWP)
motif of indolicidin is removed by C-terminal truncation,
RIN-69 (Figure 4A) remains as potent as the natural peptide
(Figure 4B) suggesting that the PWWP motif and the two Arg
residues present at the C-terminus of indolicidin are not
necessary for abDNA crosslinking. In contrast, when the
peptide is truncated from the N-terminus to leave part of
the PWWP motif and two Pro residues at the C-terminus,
the resulting RIN-66 peptide fails to crosslink abDNA
(Figure 4A). This demonstrates that the N-terminal portion
of indolicidin is required for DNA binding.
Finally, we wanted to evaluate the importance of the single
lysine residue of indolicidin. The peptide RIN-85 is derived
from RIN-25 by a single Lys to Gly mutation (Figure 4A).
Figure 4. The amino acid portion of indolicidin and RIN-25 containing the
lysine residue is critical for abasic site crosslinking. (A) sequences of the
peptides used. (B) Crosslinking formation curves of dose-response experi-
ments. Error bars indicate SD for at least three independent experiements.
Figure 3. Concentration response and kinetics of crosslinking of indolicidin
to an abDNA. (A) left panel: Representative gel of a typical dose-response
experiment; right panel: Gel of a control experiment showing that reduction
by sodium borohydride is required for crosslinking formation. (B) Represen-
tative gel of a typical kinetics experiment in the presence of indolicidin
at 37 mM. (C) upper panel: DNA sequence of the oligonucleotides used.
The box indicates the DNA position range where a single abasic site has
been introduced. Asterisk indicates labeling with
32P at the 50 end of the
DNA; lower panel: representative gel of a crosslinking experiment on DNA
oligonucleotides containing a single abasic site at the indicated 12 different
positions. An intermediate minor band corresponding to the crosslink of
indolicidin to the oligonucleotide cleaved at the abasic site after b-elimination
appears on the gel from positions  6t o 11.
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reduction in efﬁciency as compared to RIN-25 (Figure 4B).
These results suggest that the Lys residue signiﬁcantly facil-
itates but is not absolutely required for crosslinking.
Our data demonstrate that the N-terminal sequence of
indolicidin is required for DNA binding and that the presence
of the single Lys residue promotes DNA binding.
The indolicidin lysine residue and both terminal
NH2 groups all contribute to DNA binding
We next investigated the inﬂuence of indolicidin NH2 groups
on the efﬁciency of abDNA crosslinking. Dose-response
crosslinking experiments were performed with several indo-
licidin analogs (Figure 5A). Indolicidin crosslinks abDNA
at concentrations as low as 17 nM (Figure 5B, indolicidin).
Removal of the e-amino group of the single Lys by mutation
to a Gly residue reduced crosslinking efﬁciency by  20-fold
(Figure 5B, RIN-86, see Figure 4). This suggests that the
e-amino group of single Lys is important but not absolutely
required for abDNA crosslinking.
RIN-110, a Gly mutant in which the terminal NH2 groups
were removed by acetylating the N-terminus and changing
the C-terminal amide to a carboxylic group, produced
no DNA-crosslink (Figure 5B, RIN-110). Hence, the NH2
groups present at the sequence termini play a role for DNA
binding. Crosslink formation cannot be rescued by re-
introduction of either the C-terminal or the N-terminal NH2
groups alone (Figure 5B, RIN-113 and 109, respectively)
suggesting a cumulative effect of both termini. The only
Figure 5. The lysine e-amino group and the terminal NH2 groups all contribute to the crosslinking of indolicidin to the DNA abasic site. (A) schematic
representation of the reactive NH2 groups of indolicidin. (B) representative gels of dose-response experiments are shown with corresponding peptides.
The presence of NH2 groups are schematized by grey circles.
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single Lys (Figure 5B, RIN-115) but the efﬁciency of cross-
linking is reduced by almost 1000-fold as compared with
indolicidin (Figure 5, compare RIN-115 and indolicidin).
These results conﬁrm the synergistic effect of the terminal
NH2 groups on the global crosslinking efﬁciency. Restoring
the C-terminal amide group or the N-terminal amine
increases crosslinking efﬁciency by  10-fold (Figure 5B,
RIN-112 and 114, respectively) but the crosslinking level
remains  100-fold lower than the one obtained with indolici-
din (Figure 5, compare RIN-112 and 114 to indolicidin). The
guanidino groups of the two Arg residues do not seem to
inﬂuence crosslinking efﬁciency since similar results were
obtained with a series of RIN-25 derivatives that contains
two Pro residues in place of the two Arg residues (data not
shown).
Together, these results suggest that the NH2 groups present
on the Lys residue and on both termini play a synergistic role
in the crosslinking of indolicidin to abDNA.
Indolicidin interacts with DNA in the
absence of an abasic site
To demonstrate that indolicidin also interacts non-covalently
with native DNA, the MS footprinting approach was
employed (23–25). This method uses the primary amine-
modifying reagent NHS-biotin to compare surface topologies
of free peptide versus the peptide-ligand complex.
To obtain plausible footprinting results, it was important to
perform NHS-biotin treatments under mild conditions where
the integrity of the peptide–ligand complexes would be pre-
served. Our previous experience indicated that the optimal
concentration range for NHS-biotin is from 50 to 400 mM
(23–25). Incubation of free indolicidin (p1, Figure 6A) with
50 mM reagent results in peak p2 corresponding to the addi-
tion of one biotin molecule to the free peptide (Figure 6B).
MS/MS analysis of p2 indicates that the single Lys residue
is the major modiﬁed site (data not shown). An additional
modiﬁcation is detected at the N-terminus when the NHS-
biotin concentration is signiﬁcantly increased in the reaction
mixture. These observations are consistent with our previous
ﬁndings that Lys side chains exhibit signiﬁcantly higher che-
mical reactivity compared with N-terminal NH2 groups (26).
We next analyzed indolicidin interactions with native DNA
(21mer duplex IN substrate). Figure 6C indicates a strong
protection of the modiﬁed p2 peak due to direct DNA binding
of the peptide. For a control, we used a peptide of random
sequence (HDMNKVLDL) that like indolicidin has a single
Lys residue but does not inhibit IN activity. Extents of Lys
modiﬁcation in free peptides and peptide-DNA mixtures
(Figure 6E and F) are comparable suggesting that the control
peptide does not form a complex with DNA.
Finally, we used the same technique to address the ques-
tion whether indolicidin can directly interact with IN. In the
control experiments, indolicidin is incubated with BSA. Since
both IN and BSA contain surface exposed Lys residues which
provide alternative reactive sites, NHS-biotin concentration
was increased to 200 mM to achieve detectable modiﬁcation
of indolicidin in the presence of the proteins. The results
in Figure 6G and H indicate that the extents of modiﬁcation
of indolicidin in the presence of IN and BSA are very similar.
Taken together, the MS footprinting results demonstrate that
indolicidin binds non covalently to native DNA but not to IN,
suggesting that the indolicidin inhibits IN catalytic activity by
interfering with the formation of IN–DNA complex.
Indolicidin inhibits topoisomerase
I-mediated DNA relaxation
To further examine the binding of indolicidin to native DNA,
we tested whether indolicidin could interfere with human
DNA topoisomerase I activity (Top1). Top1 is ubiquitous
and essential as it relaxes DNA supercoiling during replica-
tion and transcription [for a review see (27,28)]. Relaxation
of fX174 DNA by Top1 is reduced by indolicidin when
compared with the Top1-mediated fX174 DNA reaction in
the absence of drug (Figure 7A). This inhibition of Top1 is
indolicidin concentration-dependent. Therefore, indolicidin
inhibits Top1 catalytic activity.
An unwinding assay using supercoiled DNA in the pre-
sence of Top1 is a simple procedure to detect DNA interca-
lation (22). Figure 7 (Panel B) shows that indolicidin has no
detectable effect on Top1-mediated unwinding of fX174
DNA. These results suggest that indolicidin is not a DNA
intercalator up to a concentration of 37 mM.
DISCUSSION
We previously reported that the natural cationic tridecapep-
tide indolicidin inhibits HIV-1 IN catalytic activity in vitro
(2). The present study elucidates the mechanism of action
of indolicidin. Our crosslinking and MS footprinting experi-
ments indicate that indolicidin interferes with the formation
of the IN–DNA complex by directly binding to DNA and
not to IN. Indolicidin also interferes with Top1-mediated
DNA relaxation without unwinding DNA, suggesting that
indolicidin may inhibit a large variety of DNA processing
enzymes through DNA binding. It is generally admitted
that cathelicidin HDPs (including indolicidin) exert their
broad range of biological activities through interactions
with cell membranes (15–17); but it is becoming increasingly
clear that they can also interfere with other cellular mechan-
isms. It is possible that formation of plasma membrane
‘pores’ would contribute to cellular entry. Our study and
others [for a review, see (5)] strongly suggest that cathelicidin
HDPs can inhibit biological processes by targeting nucleic
acids.
In addition to inhibiting DNA processing enzymes, indo-
licidin binds directly to abDNA. Our mass spectroscopy
(Figure 6) and Top1 inhibition results (Figure 7) are con-
sistent with a recently published study showing that indo-
licidin binds to native double-stranded DNA (14). However,
our dose-response and kinetics experiments demonstrate
that indolicidin crosslinks both double- and single-stranded
abDNA with similar efﬁciency at various DNA positions
on the HIV-1 U5 LTR DNA and without requirement for
divalent metal. The preferential binding of indolicidin to nor-
mal double-stranded DNA was observed by surface plasmon
resonance (SPR) (14), which measures afﬁnity after equili-
brium is reached. In our crosslinking experiments, the system
does not reach equilibrium since the generation of covalent
complexes is extremely fast. Thus, the strong afﬁnity of
5162 Nucleic Acids Research, 2006, Vol. 34, No. 18indolicidin for abasic sites may mask the differential afﬁnity
for single versus double-stranded DNA.
Indolicidin contains a PWWP amino acid motif, which
creates a center of symmetry in the peptide. PWWP motifs
are found in nuclear proteins such as hepatoma derived
growth factors (HDGF) and DNA metyltransferase proteins.
PWWP domains are involved in DNA binding (29,30).
Another example of a PWWP domain-containing protein is
the lens epithelium-derived growth factor (LEDGF/p75)
(31), which directly binds HIV-1 IN (32) and facilitates its
tethering to chromosome [for review see, (33)]. Truncation
of the PWWP motif from the C-terminus portion of indolici-
din did not affect crosslinking efﬁciency demonstrating that
both the PWWP motif and the two Arg residues present at
the C-terminus of indolicidin do not inﬂuence crosslinking
to abDNA. In contrast, the N-terminal portion of indolicidin
is required for efﬁcient binding to abasic sites. The single
Lys residue is directly involved in binding to native DNA
as indicated by our MS footprinting results (Figure 6). It is
also involved but not absolutely critical in the binding to
Figure 6. MALDI-TOF data depicting mass spectrometric footprinting results on indolicidin interactions with DNA and IN. In parallel experiments, interactions
of indolicidin (A–C) and interactions of a control peptide (D–F) with DNA were compared. (A and D) unmodified peptides. (B and E)2 0mM peptides were
modified with 50 mM NHS-biotin. (C and F) peptides were first incubated with 40 mM DNA and then exposed to the NHS-biotin treatment. (G and H) indolicidin
interactions with IN and BSA were compared. (G)2 0mM indolicidin was pre-incubated with 50 mM IN and then exposed to 200 mM NHS-biotin. (H)2 0mM
indolicidin was pre-incubated with 50 mM BSA and then exposed to 200 mM NHS-biotin. Peaks p1 and p2 correspond to native and biotinylated indolicidin,
respectively. Peaks p3 and p4 correspond to native and biotinylated control peptide, respectively. Sodium adducts of indolicidin and the control peptide are
indicated by ‘star’ signs.
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 20-fold reduction of crosslinking efﬁciency.
In addition to the inﬂuence of the single Lys residue, the
N- and C-terminal NH2 groups also contribute to the binding
to abDNA. Removal of one of these three NH2 groups results
in a  20- to 100-fold reduction in the crosslinking efﬁciency.
Removal of two of them abrogates crosslinking completely
except when the single Lys residue remains in the peptide.
This peptide with no terminal NH2 groups crosslinks
 1000-fold less efﬁciently than indolicidin. Therefore, the
presence of each of these three NH2 groups has a synergistic
effect on the binding to abDNA.
SIGNIFICANCE
HDPs are presently under a focus of interest as they may offer
a novel therapeutic alternative to current anti-infective thera-
pies. Our study brings new insights on the mechanism of
action of indolicidin with the possibility that this natural pep-
tide may target DNA processing enzymes. In particular, the
ability of indolicidin to bind to abDNA represents a novel
feature that may play a role in the biological activity of this
cathelicidin HDP. Abasic sites are considered to be the most
frequent DNA lesions in mammalian cells with an estimated
frequency of 10000 events per day per cell (34). Therefore
further investigations on the potential interference of indo-
licidin with DNA repair mechanisms are warranted.
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